Cynata Therapeutics Ltd has released a press release.
Efficacy for CYP MSC Technology in Preclinical Asthma Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- UK Regulatory Authority Approves Cynata GvHD Clinical Trial
- CYP Determines not to proceed with Regience Investment Offer
- CYP & FUJIFILM Sign Non-Binding Terms Sheet
- Cynata Files Application to Commence Phase 1 Clinical Trial
- Cynata Receives Investment Offer from Regience
Later from Cynata Therapeutics
- Activities Report & Appendix 4C
- Cynata Receives $1.749m R&D Tax Incentive Refund
- Cynata Files Further Patent Application
- Cynata Receives NHS HRA Approval for Clinical Study
- Cynatas Clinical Study Approved in Austrralia
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics